Why is rare variant detection and discovery from cfDNA so challenging?
Studies have shown that both cfDNA and ctDNA correlate with disease progression and reoccurrence and assist in therapy guidance. But cfDNA is highly fragmented, unstable in biofluids and at low concentrations in non-advanced, non-metastatic cancers. Meanwhile, ctDNA represents just 1–2% of total cfDNA. Add in sequencing reaction errors, enrichment biases and false positives, and you will need a lower limit of detection (LOD) of about 0.1% variant allele frequency (VAF) to find those valuable insights. To be confident in your rare variant identification, cfDNA requires highly sensitive and specific techniques.

Join us for a webinar discussing the newest technology for reliable detection of ultra-rare variants at a 0.1% VAF from cfDNA and go from sample to sequencing-ready library in just 8 hours. We will discuss the following:

  • The biggest challenges in liquid biopsy variant detection
  • Our new QIAseq chemistry and workflow
  • Simplified data analysis with our integrated bioinformatics pipeline

Explore how our new QIAseq Targeted cfDNA Ultra Panels can help you unlock the potential in your liquid biopsy samples. 

About the speaker
Krishna Amin, Senior Global Product Manager-Targeted Genomics
QIAGEN
Krishna Amin hold Bachelor of Science in Biochemistry from University of Maryland, QIAGEN. Since joining QIAGEN in 2011, she has worked with various technology development groups working on qPCR and next-generation sequencing (NGS) technologies. Currently, she leads the Targeted DNAseq portfolio at QIAGEN.
Date of recording:2023년 6월 19일 월요일
Duration:60 minutes
Categories
Webinar
Oncology
Biomarker
Next Generation Sequencing
Liquid Biopsy